Updates from ASH 2016
Number 30 • April 2017
Table of Contents
- Efficacy of daratumumab, lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone for R/R MM among patients with 1–3 prior lines of therapy based on previous treatment exposure: Updated analysis of POLLUX. (Moreau P, et al. ASH 2016:489)
- Efficacy of daratumumab, lenalidomide and dexamethasone versus lenalidomide and dexamethasone in R/R MM among patients with 1–3 prior lines of therapy: Updated analysis of POLLUX. (Usmani SZ, et al. ASH 2016:1151)
- Brief Perspective – Dr. Richard LeBlanc: Impressive Results from the POLLUX Trial
- Efficacy of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in R/R MM based on prior lines of therapy: Updated analysis of CASTOR. (Mateos MV, et al. ASH 2016:1150)
- Results of an early access program of daratumumab in U.S. patients with R/R MM. (Chari A, et al. ASH 2016:2133)
- Brief Perspective – Dr. Neil Berinstein: Perspective on an Early Access Treatment Protocol of Daratumumab in Patients with R/R Multiple Myeloma
- Use of montelukast to reduce infusion reactions in an early access program of daratumumab in U.S. patients with R/R MM. (Chari A, et al. ASH 2016:2142)
- Brief Perspective – Dr. Neil Berinstein: Use of Montelukast in Patients with R/R Multiple Myeloma Receiving Daratumumab
Chronic Lymphocytic Leukemia
- Favourable toxicity profile and long-term outcome of elderly, physically fit CLL patients receiving first-line BR chemoimmunotherapy in comparison to FCR in advanced CLL: Update analysis of the CLL10 study. (Eichhorst BF, et al. ASH 2016:4382)
- Canadian Perspective – A Canadian Perspective by Dr. Carolyn Owen on the Updated Analysis of the CLL10 Study that Examined Long-term Outcome of First- line BR Therapy Compared to FCR in Fit, Elderly Patients with CLL
- Updated analysis of overall survival in randomized phase III study of idelalisib in combination with BR in patients with relapsed/ refractory CLL. (Zelenetz AD, et al. ASH 2016:231)
- Five-year experience with single-agent ibrutinib in patients with previously untreated and relapsed/refractory CLL/SLL. (O’Brien SM, et al. ASH 2016:233)
- Updated efficacy and safety from the phase III RESONATETM-2 study: Ibrutinib as a first-line treatment option in patients 65 years and older with CLL/SLL. (Barr PM, et al. ASH 2016:234)
- Brief Perspective – Dr. Joseph Connors: Insights on Ibrutinib Treatment for Patients with CLL/SLL
- Brief Perspective – Dr. Anthea Peters: Commentary on Updated Efficacy and Safety from the RESONATE™-2 Study
- Integrated and long-term safety analysis of ibrutinib in patients with CLL/SLL. (Coutre S, et al. ASH 2016:4383)
- Analysis of the randomized trial, APL2006, on whether arsenic trioxide is required in the treatment of high-risk, newly diagnosed APL. (Ades L, et al. ASH 2016:895)
- ATRA, ATO, and gemtuzumab ozogamicin are safe and highly effective in patients with previously untreated high-risk APL: Final results from SWOG/Alliance/ECOG S0535 Trial. (Lancet JE, et al. ASH 2016:896)
- Reduction of early deaths and improved survival in elderly patients (>60 years) with APL as a result of using a simplified treatment algorithm and expert support: A prospective multicentre trial. (Kota V, et al. ASH 2016:1622)
- Real-life experience with ATRA- and ATO-based regimen in APL: Updated results of the prospective German intergroup Napoleon registry. (Platzbecker U, et al. ASH 2016:2815)
- Results from a randomized study of pegaspargase and calaspargase pegol in pediatric patients with newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma. (Silverman LB, et al. ASH 2016:175)
- Anti-pegaspargase, anti-calaspargase pegol, and anti-polyethylene glycol antibody incidence in high-risk ALL patients receiving pegaspargase or calaspargase pegol and associated anaphylactic or hypersensitivity reaction rates. (Schore RJ, et al. ASH 2016:3965)
- Obinutuzumab plus bendamustine followed by obinutuzumab maintenance prolongs OS compared with bendamustine alone in patients with rituximab-refractory iNHL: Updated results of the GADOLIN study. (Cheson BD, et al. ASH 2016:615)
- Investigator Commentary – An Interview with Dr. Bruce Cheson on the GADOLIN Study
- Autologous stem cell transplantation with Benda-EAM in aggressive NHL and Hodgkin lymphoma. (Noesslinger T, et al. ASH 2016:2265)
- Obinutuzumab-based induction and maintenance prolongs PFS in patients with previously untreated FL: Primary results of the randomized phase III GALLIUM study. (Marcus R, et al. ASH 2016:6)
- Rituximab, bendamustine and cytarabine as induction therapy in elderly patients with MCL: Final results of a phase II study from the Fondazione Italiana Linfomi. (Visco C, et al. ASH 2016:472)
- Bendamustine and rituximab versus dexamethasone, rituximab, and cyclophosphamide in patients with Waldenström Macroglobulinemia. (Paludo J, et al. ASH 2016:2968)
- Multicentre open-label phase II study of ibrutinib in chronic graft versus host disease after failure of corticosteroids. (Miklos D, et al. ASH 2016:LBA-3)
Neil Berinstein, MD, FRCPC, ABIM
Dr. Neil Berinstein earned his premedical degree and medical doctorate from the University of Manitoba and received further specialty and research training at the University of Toronto and Stanford University. Dr. Berinstein currently holds multiple academic and professional positions, including Professor in the Department of Medicine at the University of Toronto, and is an active staff member of the Hematology Oncology Site Group in the Odette Cancer Program at the Sunnybrook Health Sciences Centre. He is currently the Director of Translational Research at the Ontario Institute for Cancer Research. Dr. Berinstein specializes in the management and research of patients with lymphoproliferative disorders, including non-Hodgkin lymphoma, chronic lymphocytic leukemia, Hodgkin lymphoma, and myeloma.
Bruce D. Cheson, MD, FACP, FAAS, FASCO
Dr. Bruce Cheson completed his internship and residency in Internal Medicine at the University of Virginia Hospitals and then a clinical and research fellowship in Hematology at New England Medical Center Hospital. He is former Editor-in-Chief of Clinical Advances in Hematology and Oncology and Clinical Lymphoma, Leukemia and Myeloma, and a former Associate Editor of the Journal of Clinical Oncology. From 2002 to 2006, he was on the Oncologic Drug Advisory Committee to the U.S. Food and Drug Administration. He is past-Chair of the Lymphoma Committee of the Cancer and Leukemia Group B/Alliance, the Scientific Advisory Board of the Lymphoma Research Foundation, and the American Joint Committee on Cancer (AJCC) Subcommittee on Lymphoma. Currently, Dr. Cheson is Professor of Medicine, Head of Hematology, and Deputy Chief of Hematology-Oncology at Georgetown University Hospital, Lombardi Comprehensive Cancer Center. Dr. Cheson’s clinical interests focus on the development and evaluation of new therapeutic approaches for hematologic malignancies.
Joseph Connors, MD, FRCPC
Dr. Joseph Connors earned his medical degree from Yale University. He completed his residency training in Internal Medicine and chief residency at the University of North Carolina in Chapel Hill. Prior to completing his Medical Oncology Fellowship at Stanford University, he worked at the Indian Health Service in Alaska for two years. In 1981, he accepted a position in Medical Oncology at the BC Cancer Agency. He has been a member of the Faculty of Medicine at the University of British Columbia since that time, reaching the position of Clinical Professor in 1997. At present, he is a Clinical Professor in the Department of Medicine, Division of Medical Oncology, at the University of British Columbia and the Chair of the Lymphoma Tumour Group for the BC Cancer Agency. Dr. Connors’ clinical activities and research efforts are focused in the area of lymphoid cancers. He is best known for his clinical investigations into the treatment of Hodgkin lymphoma, non-Hodgkin lymphoma, chronic lymphocytic leukemia, and multiple myeloma.
Richard LeBlanc, MD, FRCPC
Dr. Richard LeBlanc is a hematologist and medical oncologist at Hôpital Maisonneuve-Rosemont in Montreal, Quebec. He is also a Clinical Assistant Professor of Medicine at the University of Montreal. Dr. LeBlanc obtained his medical degree at Laval University and is certified in Internal Medicine, Hematology, and Medical Oncology. He worked as a research fellow at the Dana Farber Cancer Institute in Boston from 2000 to 2002. Dr. LeBlanc was recruited by Hôpital Maisonneuve-Rosemont to help improve medical care, research, and teaching in multiple myeloma. Dr. LeBlanc holds the Myeloma Canada Chair at the University of Montreal. He is the Director of the Myeloma Cell Bank at Hôpital Maisonneuve-Rosemont, which is affiliated with the Quebec Leukemia Cell Bank. He is also the Medical Director of the Clinical Immunology Laboratory at Hôpital Maisonneuve-Rosemont. Finally, Dr. LeBlanc is a member of the Scientific Advisory Board of Myeloma Canada.
Carolyn Owen, MD, FRCPC
Dr. Carolyn Owen completed postgraduate training in internal medicine and hematology at the University of Ottawa and the University of British Columbia, respectively, followed by a research fellowship in molecular genetics at Barts and the London School of Medicine and Dentistry in London, U.K. Her research focused on familial myelodysplasia and acute myeloid leukemia. She is currently an Assistant Professor at the Foothills Medical Centre and Tom Baker Cancer Centre, University of Calgary, and her clinical interests are low-grade lymphoma and chronic lymphocytic leukemia. She is also the local principal investigator in Calgary for several clinical trials in these areas.
Anthea Peters, MD, FRCPC
Dr. Anthea Peters obtained her medical degree from the University of Saskatchewan in 2006. She then completed her residencies in Internal Medicine at the University of Alberta and in Hematology at the University of Calgary. Dr. Peters joined the Division of Hematology at the University of Alberta as a Clinical Scholar in July 2011. Her main area of interest is in lymphoma.